FDA Considers “New Paradigm” To Facilitate Third Class Of Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Approach that “under conditions of safe use” would allow nonprescription access to some categories of Rx drugs for treating chronic conditions is among topics for FDA hearing on switching Rx products to behind-the-counter status or other alternative routes.
You may also be interested in...
Since 2012, No Shortage Of Variety In US OTC Switches While Short Of Chronic Conditions
From intranasal corticosteroids to a lice treatment, and from an addition to the OTC PPI market to the first nonprescription acne drug reaching the market through an NDA, US OTC switches in the past 10 years, since FDA began considering widening switch opportunities, haven’t lacked for variety.
Statin Labeling Changes Include Class Warning About Glucose Effects
All statin labels now warn that “increases in HbA1C and fasting serum glucose levels have been reported” with the cholesterol-lowering drugs. Labels also reflect a relaxation of hepatic monitoring requirements, which could remove one hurdle to Pfizer’s pursuit of an OTC switch for Lipitor.
Statin Labeling Changes Include Class Warning About Glucose Effects
All statin labels now warn that “increases in HbA1C and fasting serum glucose levels have been reported” with the cholesterol-lowering drugs. Labels also reflect a relaxation of hepatic monitoring requirements, which could remove one hurdle to Pfizer’s pursuit of an OTC switch for Lipitor.